Is Arimidex (anastrozole) an immunosuppressant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

No, Arimidex (anastrozole) is not an immunosuppressant. It is an aromatase inhibitor primarily used in the treatment of breast cancer in postmenopausal women. Arimidex works by blocking the enzyme aromatase, which is responsible for converting androgens into estrogens, thereby reducing estrogen levels in the body. This mechanism is particularly important for treating hormone receptor-positive breast cancers that depend on estrogen for growth. Unlike immunosuppressants, which deliberately weaken the immune system to prevent rejection of transplanted organs or to treat autoimmune diseases, Arimidex does not directly affect immune function.

Common side effects of Arimidex include joint pain, hot flashes, weakness, and mood changes, but these are not related to immunosuppression. The typical dose for breast cancer treatment is 1 mg taken orally once daily. While Arimidex may have some impact on bone health by reducing estrogen (which can lead to decreased bone density), this is distinct from immunosuppressive effects. According to the study by 1, the use of anastrozole for breast cancer treatment has been shown to be effective in reducing the risk of invasive breast cancer in postmenopausal women.

The guidelines provided by 1 recommend the use of anastrozole as an alternative to tamoxifen, raloxifene, or exemestane to reduce the risk of invasive breast cancer in postmenopausal women at increased risk of developing breast cancer. Additionally, the study by 1 highlights the importance of monitoring bone health in patients taking anastrozole, as it may lead to decreased bone density.

Overall, the evidence suggests that Arimidex is a safe and effective treatment option for breast cancer in postmenopausal women, with a distinct mechanism of action that does not involve immunosuppression.

Key points to consider:

  • Arimidex is an aromatase inhibitor, not an immunosuppressant
  • It is used to treat hormone receptor-positive breast cancer in postmenopausal women
  • Common side effects include joint pain, hot flashes, weakness, and mood changes
  • The typical dose is 1 mg taken orally once daily
  • Arimidex may impact bone health, but this is distinct from immunosuppressive effects
  • Guidelines recommend the use of anastrozole as an alternative to other treatments for breast cancer risk reduction in postmenopausal women.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Arimidex and Immunosuppression

  • There is no direct evidence in the provided studies to suggest that Arimidex (anastrozole) is an immunosuppressant 2, 3, 4, 5, 6.
  • The studies primarily focus on the use of anastrozole in the treatment of breast cancer, particularly in postmenopausal women, and its effects on estrogen levels and cancer recurrence.
  • Anastrozole is described as an aromatase inhibitor, which works by preventing the conversion of androgen substrates to estrogen, thereby reducing estrogen levels in the body 4.
  • The potential immunosuppressive effects of anastrozole are not discussed in the provided studies, and therefore, it is unclear whether Arimidex has any immunosuppressive properties based on the available evidence.

Mechanism of Action

  • Anastrozole's mechanism of action is well-documented, involving the inhibition of aromatase, an enzyme responsible for converting androgens to estrogens 3, 4, 5.
  • This inhibition leads to a decrease in estrogen levels, which can help to slow the growth of hormone-sensitive breast cancer cells.
  • The studies do not mention any effects of anastrozole on the immune system or its potential use as an immunosuppressant.

Clinical Use

  • Anastrozole is approved for use in the treatment of breast cancer in postmenopausal women, particularly for hormone receptor-positive tumors 2, 3, 6.
  • The drug has been shown to be effective in reducing the risk of breast cancer recurrence and improving survival rates in this patient population.
  • However, its potential use as an immunosuppressant is not supported by the available evidence, and further research would be needed to fully understand its effects on the immune system.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.